Intervention | Study | Location | N | Study design |
Clinical decision rules (Canadian clinical decision rules 1, 2, 3; Ottawa SAH Rule) | Bellolio et al13 | USA | 454 | Retrospective cohort |
Cheung et al14 | Hong Kong | 500 | Retrospective cohort | |
Chu et al15 | Australia | 137 | Retrospective cohort (substudy of a prospective cohort) | |
Kelly et al16 | Australia | 59 | Retrospective cohort | |
MacDonald et al17 | UK | 280 | Retrospective cohort | |
Matloob et al18 | UK | 112 | Retrospective cohort | |
Pathan et al19 | UK | 145 | Retrospective cohort | |
Perry et al20 | Canada | 1999 | Prospective cohort | |
Perry et al21 | Canada | 2131 | Prospective cohort | |
Perry et al22 | Canada | 1153; overlap with Perry et al23 | Prospective cohort | |
Perry et al23 | Canada | 3672 | Prospective before/after | |
Wu et al24 | Taiwan | 913 | Retrospective cohort | |
Yiangou et al25 | UK | 162 | Retrospective cohort | |
CT–LP pathway | Blok et al26 | The Netherlands | 760 | Retrospective cohort |
Cooper et al7 | UK | 517 | Retrospective cohort | |
Dutto et al27 | Italy | 70 | Before/After | |
Perry et al28 | Canada | 891 | Retrospective cohort | |
Perry et al29 | Canada | 592 | Prospective cohort | |
Valle Alonso et al30 | Spain | 74 | Retrospective cohort | |
CT | Austin et al31 | UK | 250 | Retrospective cohort |
Backes et al32 | The Netherlands | 250 | Retrospective cohort | |
Blok et al26 | The Netherlands | 760 | Retrospective cohort | |
Cooper et al7 | UK | 517 | Retrospective cohort | |
Khan et al33 | Canada | 2412; overlap with Perry et al12 | Prospective cohort (secondary analysis) | |
Perry et al20 | Canada | 1999; overlap with Perry et al12 | Prospective cohort | |
Perry et al12 | Canada | 3132 | Prospective cohort | |
Perry et al23 | Canada | 1204 had CT <6 hours | Prospective before/after | |
Valle Alonso et al30 | Spain | 85 | Retrospective cohort | |
LP | Brunell et al34 | Sweden | 453 | Retrospective cohort |
Cooper et al7 | UK | 309 had LP | Retrospective cohort | |
Dupont et al35 | USA | 117 had LP | Retrospective cohort | |
Gangloff et al36 | Canada | 706 | Retrospective cohort | |
Heiser et al37 | USA | 676 | Retrospective cohort | |
Horstman et al38 | The Netherlands | 30 | Retrospective cohort | |
Migdal et al39 | USA | 245 | Retrospective cohort | |
Perry et al40 | Canada | 220 | Prospective cohort (substudy) | |
Perry et al41 | Canada | 1739 | Prospective cohort (substudy) | |
Sansom et al42 | UK | 60 | Retrospective cohort | |
Valle Alonso et al30 | Spain | 74 had LP | Retrospective cohort | |
CTA | Alons et al44 | The Netherlands | 70 | Retrospective cohort |
Alons et al45 | The Netherlands | 88 | Retrospective cohort and meta-analysis | |
History and examination | Locker et al2 | UK | 353 | Retrospective cohort |
Perry et al46 | Canada | 747 | Prospective cohort | |
Backes et al47 | The Netherlands | 247 | Retrospective cohort |
CSF, cerebrospinal fluid; CTA, CT angiography; LP, lumbar puncture; SAH, subarachnoid haemorrhage.